The American Association for the Study of Liver Diseases (AASLD) acknowledges the recent market withdrawal of obeticholic acid (OCA) for the treatment of primary biliary cholangitis (PBC) by Intercept Pharmaceuticals. OCA has served as a second-line therapeutic option for patients with an inadequate response to ursodeoxycholic acid, and its withdrawal marks a significant change in the PBC treatment landscape.
AASLD remains committed to providing hepatology professionals with timely, evidence-based guidance. The AASLD Practice Guidelines Committee is reviewing available data and will issue an update in the near future to the Practice Guidance on Primary Biliary Cholangitis to reflect this development.
AASLD encourages clinicians to reassess individualized ongoing treatment plans and consider alternative evidence-based management strategies in accordance with current best practices.
###
About AASLD
The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients and advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.